Compare National Beverage Corp. (FIZZ) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs Mesoblast Limited — how do they compare? National Beverage Corp. trades at $30.61 (market cap $2.89B), while Mesoblast Limited trades at $14.24 (market cap $1.75B). The key difference: National Beverage Corp. is the larger of the two by market cap, and National Beverage Corp. is more actively traded (553,950 versus 239,027). Which is the better fit depends on your goals — on Pluang, investors hold National Beverage Corp. for 33 Days and Mesoblast Limited for 15 Days on average.
| FIZZ | MESO | |
|---|---|---|
Market Cap | $2.89B | $1.75B |
Volume | 553,950 | 239,027 |
Sector | Consumer Staples | Health |
52-Week High | $37.73 | $20.96 |
52-Week Low | $29.20 | $13.19 |
Typical Hold Time | 33 Days | 15 Days |
Enterprise Value | $2.84B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
National Beverage Corp. (FIZZ) trades at $30.52, up 3.11% today, showing mixed signals with a bullish technical outlook but bearish analyst sentiment. The company reported flat revenue of $1.2B in 2025 with net income of $186.82M, while recent quarterly earnings have missed expectations. Technical indicators show support at $30 and resistance at $31, with RSI in neutral territory. Recent news highlights margin pressure from tariffs and a $3.25 special dividend payment.
FIZZ faces headwinds from stalled revenue growth and margin compression, though strong profitability metrics (40.13% ROE) provide some support. Analyst consensus is cautious with 50% sell ratings, while institutional activity shows mixed positioning. The stock's valuation appears reasonable at 16.58 P/E, but investors should monitor earnings recovery and competitive pressures in the beverage sector.
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
